Jian Irish - 05 Sep 2025 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role: Chief Executive Officer, Director
Signature: /s/ Matthew L. Wein, attorney-in-fact
Issuer symbol: MGX
Transactions as of: 05 Sep 2025
Transactions value $: $394,700
Form type: 4
Filing time: 01 Dec 2025, 19:28:00 UTC
Previous filing: 09 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Irish Jian	Chief Executive Officer, Director	C/O METAGENOMI, INC., 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE	/s/ Matthew L. Wein, attorney-in-fact	01 Dec 2025	0001995697

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MGX	Common Stock	Sale	-$2.9K	-1.6K	-0.5%	$1.81	317K	05 Sep 2025	Direct	F1, F2
transaction	MGX	Common Stock	Award	$60K	+37.5K	+11.83%	$1.60	354K	01 Dec 2025	Direct	F3
transaction	MGX	Common Stock	Award	$338K	+211K	+59.53%	$1.60	565K	01 Dec 2025	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MGX	Stock Option (Right to Buy)	Award	$0	+225K		$0.00	225K	01 Dec 2025	Common Stock	225K	$1.60	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units ("RSUs") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.
F2	Includes 1,500 shares acquired under the Company's employee stock purchase plan ("ESPP") on May 30, 2025 and 1,500 shares acquired under the Company's ESPP on November 28, 2025.
F3	These shares represent RSUs. 25% of the RSUs shall vest on December 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F4	These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F5	25% of the shares subject to this option shall vest and become exercisable on November 6, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.